Anavex Life Sciences Corp (AVXL)

[XenaLives]

Compiled: Anavex Partnerships 08/08/19
________________________________________________________________________________________________________________
INDUSTRY CONSORTIUM FOR ERP BIOMARKERS LAUNCHED:

Benefit of the Consortium:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150172628

"Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects" - Consortium sponsors.
https://clinicaltrials.gov/ct2/show/NCT04025502

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488
About erpbiomarkers.org:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147668300

Purpose of the above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169319
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150169571

Antipsychotics, also known as neuroleptics, are a class of drugs used to treat psychiatric disorders.. (from kevli33 )
https://youtu.be/nKkIh1B2Js8

Schizophrenia trial Announced:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150013370
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150015845

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488

Daniel C. Javitt, MD | Columbia University Department of Psychiatry
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147699581

Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches.
(link from georgejjl)
https://www.ncbi.nlm.nih.gov/pubmed/28890198
see also:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461562/

Larry Ereshefsky has been working on Schizophrenia for a long time:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147697607

ERP - Cognision and Anavex partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147665488
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147690818

Cognision 510K Certification:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147839850

Notes on the above from TempePhil:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179

2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307

Biostockclub holds forth on the Consortium and the history of Big Pharma:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147996854

Lima4918- opinions about the Alzheimer's Consortium:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149153359

see also NeuroNetrix below:

________________________________________________________________________________________________________________
NEURONETRIX:

Neuonetrix partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166429

Anavex CHOSE Neuronetrix for its A2-73 P2a trial for Alzh. (see Nov. 7,2014 press release).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174092
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166593

Why does Marco Cecchi (CSO of Neuronetrix) show up as the inventor in this world patent application for 2-73?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147174749

Origins of 3-71:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148063609
________________________________________________________________________________________________________________
ARIANA:

Ariana background info from Kevli 33
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147023718

Corrected link from above:
https://www.anavex.com/anavex-life-sciences-and-ariana-pharma-collaborate-to-accelerate-timelines-and-improve-efficiency-of-alzheimers-and-parkinsons-clinical-development-programs/ chi

Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/

Another article by Ariana Pharma on their website, this time highlighting the CTAD presentation:
http://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/


________________________________________________________________________________________________________________
ALZHEIMER PRECISION MEDICINE INITIATIVE:

It’s interesting that Hampel says at the end of this video. “That is why the Alzheimer Precision Medicine Initiative and Anavex is collaborating on this project.” This was most likely pointed out before but worth a second visit.
And also why Hampel uses WE when discussing the trial. How much collaboration was there?
(comment and repost from Jonjones325 on 7/7/19)

The Alzheimer Precision Medicine Initiative
Led by Harald Hampel
https://www.apmiscience.com

Cbdpotential on systems and reference to a 2017 paper by Harald Hampel:

A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149737160

Harald Hampel: “That is why the Alzheimer Precision Medicine Initiative and Anavex is collaborating on this project.”

A former member of the Anavex Scientific Advisory Board and an internationally recognized expert on Alzheimer’s and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France. The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer’s Disease (IM2A), a reference center for Alzheimer’s and other neurodegenerative diseases, and affiliated with a leading neuroscience institution, the Brain and Spine Institute (ICM), as well as the Department of Neurology at the Pitié-Salpétrière University Hospital. He has conducted more than 50 clinical trials over the past 20 years and has developed international programs focused on Alzheimer’s therapy, diagnosis and the development of biological and imaging biomarkers, including his current work as AXA-UPMC Chair, which aims to improve early detection at the preclinical ‘silent stage’ before the onset of any clinical signs and symptoms. After a post-doctoral fellowship focused on structural and functional neuroimaging of the healthy aging and Alzheimer’s disease brain at the NIH/NIA Laboratory of Neurosciences in Bethesda, MD, Dr. Hampel became founding director of the Alzheimer Memorial Center and Professor of Psychiatry at the University of Munich. In 2006, he was appointed as a Professor and Chair of Psychiatry at Trinity College, University of Dublin, Ireland. During this time, he was a leading Principal Investigator at the Trinity College Institute of Neuroscience (TCIN). In 2010, Dr. Hampel was appointed as Professor, Chair and Head of Department of Psychiatry and Co-Director of the Brain Imaging Center (BIC) at the University of Frankfurt. Dr. Hampel has published more than 500 peer-reviewed research papers, 80 book chapters and eight books, many in world-leading scientific journals, such as the New England Journal of Medicine, JAMA, The Lancet, The Lancet Neurology, Nature Genetics, Nature Reviews Drug Discovery and Nature Reviews Neurology. He has won numerous awards for his scientific work on healthy and diseased brains as well as biomarker and therapy discovery in Alzheimer’s. Additionally, Dr. Hampel has been a reviewer for leading international scientific journals and funding agencies in the US, Canada and Europe and is Senior Associate Editor of the leading international Alzheimer’s journal Alzheimer’s & Dementia, the journal of the Alzheimer’s Association.

Research Gate intro:

My objective is to transform Neurology, Psychiatry and Neuroscience embracing Precision Medicine based on Complex Systems Theory using Systems Biology and Neurophysiology, Big Data Science and Biomarker-guided Integrative Disease Modeling (IDA) for improved Detection, Classification and Therapy Development in Neurodegenerative Diseases, such as Alzheimer's disease. Towards this end I have launched the Alzheimer Precision Medicine Initiative (APMI) and the APMI cohort program (APMI-CP). Website Alzheimer Precision Medicine Initiative (APMI): https://www.apmiscience.com/

https://www.researchgate.net/profile/Harald_Hampel

Hampel's August 2018 statement on the action of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145787370

HH twitter:
https://twitter.com/harald_hampel#
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147429124

Revolution of Alzheimer Precision Neurology: Passageway of Systems Biology and Neurophysiology
Harald Hampel primary author, posted by nidan7500
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008221/#!po=0.337838

Harald Hampel tweets this paper (from kevli33):
Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450260/
https://twitter.com/harald_hampel/status/1118495219895476226

Hampel on precision Medicine and Alzheimer's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148302986

Hampel APMI bio link:
https://www.apmiscience.com/working-group-1

Dr. Harald Hampel, MD, PhD, MA, MSc: Genomic Analysis of ANAVEX 2-73 in Alzheimer Disease Study 10/18, Videos:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148601340

Hampel and precision medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138458647

Eisai names Harald Hampel VP Global Medical Affairs
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team

More on Eisai's Alzheimer's moves.... (from Talon38)
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team
https://www.biospace.com/article/eisai-continues-alzheimer-s-research-adds-2-alzheimer-s-pros-as-execs


"Our paper on plasma amyloid beat 40/42 ration predicts cerebral amyloidosis in asymptomatic at risk individuals for AD has been published in Alzheimer's & Dementia"(from kevli33 quoting Harald Hampel tweet)
https://goo.gl/scholar/JZH7Zw


_________________________________________________________________________________________
COGNISION and NEURONETRIX:

Neuonetrix partnership
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166429

Anavex CHOSE Neuronetrix for its A2-73 P2a trial for Alzh. (see Nov. 7,2014 press release).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150174092
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149166593

Why does Marco Cecchi (CSO of Neuronetrix) show up as the inventor in this world patent application for 2-73?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147174749

4/3/19 - New position paper from FDA on AI.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271
Summary of the Cecchi ERP patent application...as paid for by Anavex(applicant).
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179

Tool suite used in the Cognision patent (thanks Nidan7500):
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
https://www.advancedbrainmonitoring.com/

Link to the patent application
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147781853

New EEG techniques for Alzheimer's and other CNS disease under development, including AI:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113

A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext

P300 amplitude recovers to healthy levels over 53 weeks in the P2a and extension
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146074463

Cognision protocol for TBI (from georgejjl)
http://www.cognision.com/wp-content/uploads/2018/09/ERP-for-Diagnosis-and-Prognosis-of-Traumatic-Brain-Injury-9-18.pdf

Cognision on diagnostic process, FDA approval:
http://www.cognision.com/wp-content/uploads/2017/11/Clinical-Study-FDA-Approval.pdf

2015 mention of ERP results at five weeks:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148130307

Past posts on Cognision and Erp:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145755014

Possible approval based on sleep, with ERP/EEG taken as suporting biomarker evidence
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148919365

Cognision and ERP/EEG tracking in trials - is this why trials are adding sites slowly?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148909354

________________________________________________________________________________________________________________
McGill University:

Canadian University that does a lot of Anavex preclinical research.
https://www.mcgill.ca/neuro/

McGill, Merck and Canada's CDRD join in researh effort 2017
https://www.mcgill.ca/neuro/channels/news/health-science-leaders-join-forces-accelerate-development-treatments-neurological-diseases-267104

________________________________________________________________________________________________________________
Manufacturing Partners:

Theory on Anavex Manufacturing partner..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148205960

________________________________________________________________________________________________________________
MAYBE MERCK ????:


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149038386

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148209671

Merck Canada funding research on 2-73 and 3-71 and possibility of a combo:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148210694
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148210824
________________________________________________________________________________________________________________
Lund University:

Dr. Angela Cenci-Nilsson and Dr. Veronica Francardo's Lund University:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342353

Dr. M. Angela Cenci Nilsson resulting study from the 2015 research grant for Parkinson's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148339012
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342120
PROFILE
http://www.academia-net.org/profil/prof-dr-m-angela-cenci-nilsson/1488381

Veronica Francardo
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148342376
Francardo May 2018 statement on effect of 2-73 in Parkinson's
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134044839

Anavex PR's from the Lund preclinical research on Parkinson's by Cenci-Nilsson and Francardo.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148343391

________________________________________________________________________________________________________________
Manufacturing Partners & Potential Partners:

Theory on Anavex Manufacturing partner..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148205960

More on Eisai's Alzheimer's moves.... (from Talon38)
https://www.fiercebiotech.com/biotech/eisai-installs-new-alzheimer-s-clinical-trial-leadership-team
https://www.biospace.com/article/eisai-continues-alzheimer-s-research-adds-2-alzheimer-s-pros-as-execs